Plain-English translation of NCT07327034 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a new drug called ABSK-011 can help people with advanced liver cancer that hasn't responded to previous treatments. The medication is designed to target a specific genetic change found in some liver cancers. Researchers will compare how well ABSK-011 works compared to a placebo (an inactive pill), with both groups also receiving the best supportive care available.
Many people with advanced liver cancer eventually stop responding to standard treatments like immunotherapy and targeted drugs. This medication takes a different approach by targeting a specific genetic marker in the cancer, which may help people whose tumors have this particular change.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to receive either ABSK-011 plus supportive care or a placebo plus supportive care. You will take your assigned treatment in 28-day cycles and visit the clinic regularly for check-ups, scans, and blood tests. You will continue until your cancer gets worse, you experience side effects you cannot tolerate, or you and your doctor decide to stop—which could take several months or longer.
AI-generated summary from trial data · Jul 21, 2026 · Not medical advice
China